Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., was founded as a Delaware corporation and conducted its operations as a clinical-stage biopharmaceutical firm. Its pipeline centered on AV-101, a proprietary antagonist targeting the CB1 receptor, designed as an antidote for cannabis overdose and a potential treatment for marijuana use disorder. The firm was publicly traded on the Nasdaq Capital Market under the ticker ANEB. The company pursued a lean operating model, outsourcing preclinical and clinical development to contract research organizations. It raised capital through equity offerings and collaboration agreements, including a partnership with Celon Pharma for the distribution of AV-101 in Central and Eastern Europe. Anebulo did not disclose AUM or assets under management, as it was a biotech company, not an investment firm. In Q1 2023, Anebulo was acquired by Alvogen, a privately held pharmaceutical firm focused on generic and specialty drugs, in an all-cash merger valued at approximately $10.5 million. The deal closed in June 2023, delisting Anebulo from the Nasdaq and ending its existence as a standalone entity. No professionals or team sizes were publicly detailed. The defining structural feature of Anebulo was its status as a small-cap, publicly traded biotech with a single lead drug candidate, a model that often relies on external financing and eventual acquisition. Its governance was standard for a public company, with a board of directors and executive officers, but no public family office or wealth fund affiliation.